Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Evommune Inc. (EVMN) had Consolidated Net Income/Loss of $-66.81M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$7.00M |
|
$-66.81M |
|
-- |
|
$7.00M |
|
-- |
|
$7.00M |
|
-- |
|
$7.00M |
|
$7.00M |
|
$7.00M |
|
$-66.81M |
|
|
Consolidated Net Income/Loss |
$-66.81M |
$7.00M |
|
$7.00M |
|
$7.00M |
|
1.51M |
|
1.51M |
|
$-45.29 |
|
$-45.29 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
-954.40% |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|